Investor Presentation for March 31, 2016
FDC Ltd has informed BSE about : 1. Investor Presentation for the period ended March 31, 201626-05-2016
26-05-2016
Outcome of Board Meeting
FDC Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2016, inter alia, has recommended that the interim dividend of Rs. 2.25/- (225%) per Equity share having face value of Re. 1 each, paid on March 23, 2016, be considered as final dividend for the year ended March 31, 2016.Further, the Board Meeting commenced at 2.00 p.m. and concluded at 4.45 p.m.26-05-2016
Standalone & Consolidated Financial Results, Form A, Auditors Report for March 31, 2016
FDC Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Consolidated Financial Results for the period ended March 31, 20163. Standalone Form A for the period ended March 31, 20164. Consolidated Form A for the period ended March 31, 20165. Standalone Auditors Report for the period ended March 31, 20166. Consolidated Auditors Report for the period ended March 31, 201626-05-2016
Intimation of Conference Call
FDC Ltd has informed BSE regarding "Intimation of Conference Call".25-05-2016
Board to consider Dividend
FDC Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2016, inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2016.Also, the Company has informed that the Board will also interalia, consider the recommendation of dividend, if any, for the year ended March 31, 2016....06-05-2016
NPPA examining 92 applications to fix price of new FDCs
Also, last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend29-04-2016
Indian drug control system the weakest: Pharma secy
To ensure quality, the government banned 344 fixed drug combinations (FDCs) on March 1020-04-2016
HC asks govt the need to ban 300 FDC drugs
HC asks govt the need to ban 300 FDC drugs What was the urgency for banning the manufacture and sale of over 300 FDC medicines and how can approval DCGI be disregarded completely, Delhi HC asked.18-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
FDC Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.15-04-2016